Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dapagliflozin Faces Ominous Prospect Of New Trials

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s rejection of Bristol-Myers Squibb and AstraZeneca’s diabetes drug dapagliflozin may mean new trials are needed, which would be a blow for the drug as well as a bad sign for the new class of SGLT2 inhibitors.

You may also be interested in...

FDA Panel To Weigh Dapagliflozin Bladder Cancer, CV Safety Questions

Endocrinologic and Metabolic Drugs Advisory Committee will revisit concerns first discussed at 2011 meeting about bladder cancer risk with Bristol/AstraZeneca’s diabetes drug. Cardiovascular meta-analysis continues to suggest benefit but FDA questions what to make of “discordant” results from two studies in patients with CV disease.

SGLT-2 Inhibitor Dapagliflozin Gets Another Chance At FDA

FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will consider a new submission for AstraZeneca/Bristol-Myers Squibb’s dapagliflozin on Dec. 12. Filing includes several new studies and more long-term data.

2013 May Still Be A Trough Year For Bristol As New Drugs Continue To Take Hold

Bristol remains plagued by the loss of exclusivity for Plavix and setbacks in 2012, but the company hopes to paint a picture of growth as newly approved drugs begin to fill the revenue gap.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts